Current Report Filing (8-k)
September 12 2019 - 3:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 12, 2019
RITTER
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37428
|
|
26-3474527
|
(State
or other
jurisdiction
of incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
1880
Century Park East, Suite 1000
|
|
|
Los Angeles, California
|
|
90067
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (310) 203-1000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities Registered Pursuant to Section 12(b) of the Exchange Act:
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of Each Exchange on Which Registered
|
Common
Stock, par value $0.001
|
|
RTTR
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On
September 12, 2019, Ritter Pharmaceuticals, Inc. issued a press release announcing top-line results from its Liberatus Phase 3
Trial of RP-G28 for lactose intolerance. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein
by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
RITTER PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Andrew J. Ritter
|
|
Name:
|
Andrew J. Ritter
|
|
Title:
|
Chief Executive Officer
|
Date:
September 12, 2019
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Apr 2024 to May 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Ritter Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Ritter Pharmaceuticals Inc News Articles